Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10423946 | 1.00 | ALDH1A1 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL6419814 | 1.00 | ALDH1A1 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL9214310 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL700267 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL17459233 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL11168279 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL15648022 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL5795950 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL21645278 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA | |
| SCHEMBL15436121 | 0.98 | USP2 (0.40) | ALDH1A1CNR1CNR2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240102069-A1 | METHODS AND COMPOSITIONS | PLANT BIOSCIENCE LIMITED (GB) | 2024-03-28 | — | — | US | disclosed |
| CN-117062914-A | Methods and compositions | 植物生物科学有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4267750-A2 | METHODS AND ENZYMES FOR PRODUCING QUILLAIC ACID DERIVATIVES | Plant Bioscience Limited (GB) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136563-A2 | METHODS AND COMPOSITIONS | PLANT BIOSCIENCE LIMITED (GB) | 2022-06-30 | — | — | WO | disclosed |
| US-20210395704-A1 | NANOBODY-GLYCAN MODIFYING ENZYME FUSION PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-12-23 | — | — | US | disclosed |
| US-10736973-B2 | Glucose analogs for diagnosis states | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2020-08-11 | — | — | US | disclosed |
| EP-3403662-B1 | PHARMACOACTIVE NUTRIENT AND A PROCESS OF PRODUCTION THEREOF FROM MARINE ALGAE | NATIONAL INSTITUTE OF OCEAN TECH (IN) | 2020-01-29 | — | — | EP | disclosed |
| EP-3403662-A1 | PHARMACOACTIVE NUTRIENT AND A PROCESS OF PRODUCTION THEREOF FROM MARINE ALGAE | National Institute of Ocean Technology (IN) | 2018-11-21 | — | — | EP | disclosed |
| US-10087427-B2 | Glycosyltransferase gene and use thereof | SUNTORY HOLDINGS LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| US-10059956-B2 | Glycosyltransferase gene and use thereof | SUNTORY HOLDINGS LIMITED (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20180177898-A1 | GLUCOSE ANALOGS FOR DIAGNOSIS OF DISEASE STATES | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2018-06-28 | — | — | US | disclosed |
| EP-3138908-A1 | NOVEL GLYCOSYLTRANSFERASE GENE AND USE THEREOF | Suntory Holdings Limited (JP) | 2017-03-08 | — | — | EP | disclosed |
| US-20170058269-A1 | NOVEL GLYCOSYLTRANSFERASE GENE AND USE THEREOF | SUNTORY HOLDINGS LIMITED (JP) | 2017-03-02 | — | — | US | disclosed |
| EP-3122382-A2 | GLUCOSE ANALOGS FOR DIAGNOSIS OF DISEASE STATES | Technology Innovation Momentum Fund (Israel) Limited Partnership (IL) | 2017-02-01 | — | — | EP | disclosed |
| EP-2818547-B1 | GLYCOSYLTRANSFERASE GENE AND USE THEREOF | SUNTORY HOLDINGS LTD (JP) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015145447-A2 | GLUCOSE ANALOGS FOR DIAGNOSIS OF DISEASE STATES | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2015-10-01 | — | — | WO | disclosed |
| US-20150203862-A1 | NOVEL GLYCOSYLTRANSFERASE GENE AND USE THEREOF | SUNTORY HOLDINGS LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-2818547-A1 | NOVEL GLYCOSYLTRANSFERASE GENE AND USE THEREOF | Suntory Holdings Limited (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1015564-A1 | CHAIN LENGTH SPECIFIC UDP-Glc:FATTY ACID GLUCOSYLTRANSFERASES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999009144-A1 | CHAIN LENGTH SPECIFIC UDP-Glc:FATTY ACID GLUCOSYLTRANSFERASES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395704-A1 | NANOBODY-GLYCAN MODIFYING ENZYME FUSION PROTEINS AND USES THEREOF | ENGASE, RNASE1, DNPEP | ALDH1A1 2418/4885CNR1 4742/4885CNR2 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.